HalcyGen works on IND
Friday, 18 July, 2008
Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.
The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.
It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.
According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
